Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

Related Posts

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

US appeals court sides with Sun Pharma in Lipitor antitrust case

US appeals court sides with Sun Pharma in Lipitor antitrust case

Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad